Randomized Trial of Tocilizumab in Systemic Juvenile Idiopathic Arthritis
Open Access
- 20 December 2012
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 367 (25), 2385-2395
- https://doi.org/10.1056/nejmoa1112802
Abstract
Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA; treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. We randomly assigned 112 children, 2 to 17 years of age, with active systemic JIA (duration of ≥6 months and inadequate responses to nonsteroidal antiinflammatory drugs and glucocorticoids) to the anti–interleukin-6 receptor antibody tocilizumab (at a dose of 8 mg per kilogram of body weight if the weight was ≥30 kg or 12 mg per kilogram if the weight was <30 kg) or placebo given intravenously every 2 weeks during the 12-week, double-blind phase. Patients meeting the predefined criteria for nonresponse were offered open-label tocilizumab. All patients could enter an open-label extension. At week 12, the primary end point (an absence of fever and an improvement of 30% or more on at least three of the six variables in the American College of Rheumatology [ACR] core set for JIA, with no more than one variable worsening by more than 30%) was met in significantly more patients in the tocilizumab group than in the placebo group (64 of 75 [85%] vs. 9 of 37 [24%], P<0.001). At week 52, 80% of the patients who received tocilizumab had at least 70% improvement with no fever, including 59% who had 90% improvement; in addition, 48% of the patients had no joints with active arthritis, and 52% had discontinued oral glucocorticoids. In the double-blind phase, 159 adverse events, including 60 infections (2 serious), occurred in the tocilizumab group, as compared with 38, including 15 infections, in the placebo group. In the double-blind and extension periods combined, 39 serious adverse events (0.25 per patient-year), including 18 serious infections (0.11 per patient-year), occurred in patients who received tocilizumab. Neutropenia developed in 19 patients (17 patients with grade 3 and 2 patients with grade 4), and 21 had aminotransferase levels that were more than 2.5 times the upper limit of the normal range. Tocilizumab was efficacious in severe, persistent systemic JIA. Adverse events were common and included infection, neutropenia, and increased aminotransferase levels. (Funded by Hoffmann–La Roche; ClinicalTrials.gov number, NCT00642460.)Keywords
This publication has 21 references indexed in Scilit:
- Patients with early-onset systemic juvenile idiopathic arthritis show more inflammation and worse outcomePediatric Rheumatology, 2011
- Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO)Archives of Disease in Childhood, 2011
- A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)Annals Of The Rheumatic Diseases, 2010
- The pattern of response to anti–interleukin‐1 treatment distinguishes two subsets of patients with systemic‐onset juvenile idiopathic arthritisArthritis & Rheumatism, 2008
- Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA RegistryAnnals Of The Rheumatic Diseases, 2008
- Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national registerAnnals Of The Rheumatic Diseases, 2008
- Impaired skeletal development in interleukin‐6–transgenic mice: A model for the impact of chronic inflammation on the growing skeletal systemArthritis & Rheumatism, 2006
- Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation.JCI Insight, 1997
- Measurement of health status in children with juvenile rheumatoid arthritisArthritis & Rheumatism, 1994
- Primary pulmonary hypertension in a patient with systemic‐onset juvenile arthritisArthritis & Rheumatism, 1991